Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

By the time Monte Wooden had his first heart attack, nothing about his lifestyle explained it. He didn’t smoke. His blood ...

A poll conducted in April and May of 2024 found that around 12 percent of Americans have tried a GLP-1 drug such as Ozempic, Wegovy, Zepbound, or Mounjaro—a number that has likely only grown ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England ...

WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...